RYDAPT Drug Patent Profile

When do Rydapt patents expire, and what generic alternatives are available?

Rydapt is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-two patent family members in twenty-seven countries.

The generic ingredient in RYDAPT is midostaurin. One supplier is listed for this compound. Additional details are available on the midostaurin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rydapt

A generic version of RYDAPT was approved as midostaurin by LUPIN on May 10^th, 2024.

Summary for RYDAPT

International Patents:	62
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	53
Clinical Trials:	12
Patent Applications:	4,991
Drug Prices:	Drug price information for RYDAPT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RYDAPT
What excipients (inactive ingredients) are in RYDAPT?	RYDAPT excipients list
DailyMed Link:	RYDAPT at DailyMed

See drug prices for RYDAPT

Recent Clinical Trials for RYDAPT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Jazz Pharmaceuticals	Phase 1/Phase 2
Baptist Health South Florida	Phase 1/Phase 2
Novartis Pharmaceuticals	Phase 1/Phase 2

See all RYDAPT clinical trials

Pharmacology for RYDAPT

Drug Class	Kinase Inhibitor
Mechanism of Action	Receptor Tyrosine Kinase Inhibitors

Paragraph IV (Patent) Challenges for RYDAPT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RYDAPT	Capsules	midostaurin	25 mg	207997	4	2021-04-28

US Patents and Regulatory Information for RYDAPT

RYDAPT is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	RYDAPT	midostaurin	CAPSULE;ORAL	207997-001	Apr 28, 2017	AB	RX	Yes	Yes	8,575,146
Novartis	RYDAPT	midostaurin	CAPSULE;ORAL	207997-001	Apr 28, 2017	AB	RX	Yes	Yes	7,973,031

Expired US Patents for RYDAPT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	RYDAPT	midostaurin	CAPSULE;ORAL	207997-001	Apr 28, 2017	8,222,244

EU/EMA Drug Approvals for RYDAPT

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novartis Europharm Ltd	Rydapt	midostaurin	EMEA/H/C/004095Rydapt is indicated:in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive (see section 4.2);as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL).	Authorised	no	no	yes	2017-09-18

International Patents for RYDAPT

See the table below for patents covering RYDAPT around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2527703	NOUVELLE UTILISATION DE DERIVES DE STAUROSPORINE (NEW PHARMACEUTICAL USES OF STAUROSPORINE DERIVATIVES)
South Korea	20050040842
Japan	5057780
Taiwan	200512213	New use of staurosporine derivatives

Supplementary Protection Certificates for RYDAPT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1638574	C20170046 00256	Estonia		PRODUCT NAME: MIDOSTAURIIN;REG NO/DATE: EU/1/17/1218 20.09.2017
1441737	18C1012	France		PRODUCT NAME: MIDOSTAURINE; REGISTRATION NO/DATE: EU/1/17/1218 20170920
1441737	C01441737/01	Switzerland		PRODUCT NAME: MIDOSTAURIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66310 04.05.2017
1638574	C01638574/01	Switzerland		PRODUCT NAME: MIDOSTAURIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66310 04.05.2017

Market Dynamics and Financial Trajectory for RYDAPT

Last updated: February 20, 2026

What is RYDAPT and What Conditions Does It Treat?

RYDAPT (midostaurin) is an oral kinase inhibitor approved by the FDA in 2017. It targets multiple molecular pathways, chiefly FLT3 mutations and mast cell disease. The drug is indicated for:

• Newly diagnosed FLT3-mutated acute myeloid leukemia (AML), combined with chemotherapy
• Advanced systemic mastocytosis (SM), including aggressive SM (ASM), systemic mastocytosis with associated hematologic neoplasm (SM-AHN), and indolent or smoldering SM (ISM)

How Has the RYDAPT Market Evolved?

Market Penetration and Sales Trends

• Launch year (2017): $150 million in global sales
• Peak sales (2020): approximately $500 million globally
• 2022 sales: roughly $460 million, indicating a plateau and minor decline
• Sales data sourced from IQVIA, 2022

Geographic Sales Breakdown

Region	2022 Sales (USD Million)	Market Share (%)
U.S.	$300	65
Europe	$100	22
Rest of World	$60	13

The U.S. dominates due to early approval and extensive clinical use, with Europe as the second-largest market. Emerging markets show limited uptake due to high costs and reimbursement barriers.

Earnings Drivers and Competitive Landscape

• Main revenue driver: FLT3-mutated AML treatment
• Competition: Gilteritinib (Xospata), approved for relapsed/refractory AML; Glasdegib (Daurismo) in AML; and potential pipeline agents targeting similar pathways
• Patent expiry: No imminent patent expiration; patent protections extend into the late 2020s

What Are the Market Drivers and Barriers?

Key Drivers

• Increasing incidence of AML: Approximately 20,000 new cases annually in the U.S. (SEER, 2022)
• Growing diagnosis rates of FLT3 mutations: Approximately 30% of AML cases in AML populations harbor FLT3 mutations
• Improving survival rates with targeted therapy: Median overall survival for FLT3-mutated AML patients improves with RYDAPT plus chemotherapy

Barriers to Growth

• High treatment cost: Estimated at $20,000 per month, limiting affordability
• Limited indications: Currently restricted to specific AML and SM subtypes
• Competition from newer agents: Gilteritinib shows favorable efficacy in relapsed AML, challenging RYDAPT’s market share
• Off-label use restrictions: Insurance coverage limits wider off-label application

What Is the Financial Trajectory Forecast?

Short-Term Outlook (2023-2025)

• Slight revenue decline expected due to market saturation and competition
• Forecasted global sales in 2023: approximately $440 million
• Potential growth from expanded indications or combination therapies remains uncertain

Mid-to-Long Term Outlook (2026-2030)

• Sales could stabilize around $300-400 million annually if existing indications persist
• Expansion into other hematologic malignancies or new molecular targets may boost revenues
• Market entry of biosimilars or lower-cost generics unlikely due to patent protection

Investment and R&D

• Novartis, which markets RYDAPT, allocated approximately $10 billion annually to R&D in 2022
• Focus on combination therapies: pairing RYDAPT with other agents to extend indications
• Potential pipeline: generic midostaurin expected around 2035, with patent expiration assumed in late 2020s

What Are the Key Opportunities and Risks?

Opportunities

• Acceleration of approval processes for novel indications
• Strategic alliances for combination therapy development
• Expanding access in emerging markets through partnerships

Risks

• Competitive pressure from newer agents with better efficacy profiles
• Regulatory setbacks or delays
• Pricing and reimbursement constraints due to high costs

Key Takeaways

• RYDAPT has established a niche in AML with FLT3 mutations and systemic mastocytosis
• Sales peaked around $500 million in 2020, with slight declines projected
• Growth relies on market expansion, pipeline developments, and competitive positioning
• Barriers include high cost, limited indications, and emerging competitors

Frequently Asked Questions

Q1: How long is RYDAPT patent protected?
A: Patent protection extends into the late 2020s, with generics expected around 2029 or 2030.

Q2: What is the primary competitor to RYDAPT?
A: Gilteritinib (Xospata) offers an alternative for relapsed AML and has some advantages in efficacy.

Q3: Are there ongoing trials for RYDAPT in other indications?
A: Yes, trials are exploring combinations with immunotherapies and potential new indications in hematologic malignancies.

Q4: How does RYDAPT's cost influence its market penetration?
A: The high monthly cost limits access, especially in cost-sensitive regions, constraining broader adoption.

Q5: What factors could significantly impact RYDAPT’s future sales?
A: Entry of biosimilars post-patent expiry and development of more effective therapies could reduce sales.

---

References

1. SEER. (2022). Cancer Stat Facts: Acute Myeloid Leukemia. National Cancer Institute.
2. IQVIA. (2022). Global Oncology Market Data.
3. Novartis. (2022). Annual Report 2022.